¶ title: Multifocal Motor Neuropathy (MMN)
description: Comprehensive review of multifocal motor neuropathy, an immune-mediated neuropathy with conduction block, including pathophysiology, clinical features, diagnosis, and treatment
published: true
tags: [neuropathy, autoimmune, motor-neuron, conduction-block]
editor: markdown
pageId: 1938
dateCreated: "2026-03-01T22:47:32.680Z"
dateUpdated: "2026-03-23T18:54:00.000Z"
Multifocal motor neuropathy (MMN) is a rare, immune-mediated peripheral neuropathy characterized by asymmetric, purely motor weakness that typically begins in the distal upper limbs and progresses in a multifocal pattern 1. The condition is distinguished by the presence of conduction block—focal slowing or failure of nerve signal transmission at specific sites—despite relatively preserved nerve structure on conventional imaging 2.
First described in the 1980s, MMN represents a distinct clinical entity within the spectrum of motor neuropathy syndromes. Unlike chronic inflammatory demyelinating polyneuropathy (CIDP), MMN affects only motor fibers, spares sensory function, and responds dramatically to intravenous immunoglobulin (IVIG) but not to corticosteroids 3. This unique responsiveness has important diagnostic and therapeutic implications.
- Prevalence: 1-2 per 100,000 population 4
- Age of onset: Typically 20-50 years (mean: 40 years)
- Gender distribution: Male predominance (M:F = 2.5:1)
- Geographic distribution: Worldwide, no ethnic predominance
- Disease course: Chronic progressive, typically over years
¶ Etiology and Pathophysiology
MMN is considered an immune-mediated disorder, though the precise antigen remains uncertain:
Approximately 30-50% of MMN patients have elevated IgM antibodies against GM1 ganglioside 5:
- Target: GM1 ganglioside on peripheral nerve myelin
- Pathogenic role:
- May activate complement cascade
- Disrupts node of Ranvier function
- Impairs motor nerve conduction
- Correlation: Higher antibody titers correlate with more severe conduction block
- Specificity: Not absolute—anti-GM1 also seen in other neuropathies
| Antibody |
Frequency |
Clinical Relevance |
| Anti-GM1 |
30-50% |
Associated with conduction block |
| Anti-GD1a |
10-20% |
May predict treatment response |
| Anti-GalNAc-GD1a |
5-10% |
Rare |
| Seronegative |
50-70% |
Similar phenotype |
- T-cell mediated demyelination: Perivascular T-cell infiltrates in nerve biopsies 6
- Macrophage involvement: Activated macrophages target myelin sheaths
- Cytokine dysregulation: Elevated TNF-α, IL-1β in affected nerves
Nerve biopsy (when performed) reveals 7:
- Focal onion bulb formation: Concentric Schwann cell processes
- Reduced myelinated fiber density: Particularly at sites of conduction block
- Minimal inflammation: Less than typical CIDP
- No axonal degeneration (early stages): Preserved axons despite demyelination
- Segmental demyelination: Focal, not diffuse
The hallmark conduction block results from:
- Demyelination at specific nerve sites (not uniform)
- Functional impairment of sodium channels at nodes of Ranvier
- Spatial dispersion of action potentials
- Temporary conduction failure under certain conditions (temperature, ischemia)
- Typically insidious: Gradual onset over weeks to months
- Initial symptoms: Weakness in hand/forearm (dominant hand often first)
- Asymmetry: Critical diagnostic feature—marked difference between limbs
- Pattern: Multifocal, affecting individual peripheral nerve territories
| Pattern |
Frequency |
Description |
| Upper limb dominant |
70-80% |
Hands and forearms initially |
| Lower limb onset |
15-20% |
Foot drop, ankle dorsiflexion weakness |
| Cranial involvement |
Rare |
Facial weakness in <5% |
| Respiratory muscles |
Rare |
Requires urgent attention |
- Slow progression: Years to decades
- Stepwise: Periods of stability interspersed with progression
- Eventually bilateral: Initially asymmetric, may become bilateral
- Distal to proximal spread: Weakness extends proximally over time
- Asymmetric weakness: Variable in different muscle groups
- Distribution: Multiple peripheral nerve territories (median, ulnar, radial, peroneal)
- Weakness pattern:
- Wrist/finger extensors
- Finger flexors
- Intrinsic hand muscles
- Ankle dorsiflexion
- Fasciculations: Present in 20-30%
- Muscle atrophy: Late finding, correlates with disease duration
- Tone: Normal or decreased
- Reflexia: Reduced or absent in affected territories
Normal sensory function is the rule:
- Pinprick: Intact
- Vibration: Intact
- Position sense: Intact
- Light touch: Intact
This is a critical distinguishing feature from CIDP and other polyneuropathies.
- Pain: Mild to moderate, in affected limb (30-40%)
- Fatigue: Generalized, may worsen with activity
- No systemic features: Unlike vasculitis or connective tissue disease
Definite MMN:
- Asymmetric motor weakness in ≥2 peripheral nerve territories
- Objective conduction block in ≥2 motor nerves
- Normal sensory nerve conduction studies
- No upper motor neuron signs
Probable MMN:
- Asymmetric motor weakness in ≥1 peripheral nerve territory
- Conduction block in ≥1 motor nerve
- Normal or minor sensory abnormalities
- No upper motor neuron signs 8
Nerve conduction studies (NCS) and electromyography (EMG) are essential:
| Finding |
Expected Result |
| Motor nerve conduction |
Focal conduction block |
| Distal motor latency |
Prolonged at block site |
| Motor conduction velocity |
Slowed across block segment |
| Compound muscle action potential |
Reduced amplitude proximally |
| Sensory nerve conduction |
Normal (key feature) |
| EMG |
Neurogenic changes, fibrillation potentials |
- Temporal dispersion: ≥30% drop in CMAP area
- Partial conduction block: ≥50% drop in CMAP amplitude
- Location: Typically at forearm level (median > ulnar > peroneal)
| Test |
Purpose |
Expected Finding |
| Anti-GM1 antibodies |
Serology |
Elevated in 30-50% |
| CSF protein |
Inflammation |
Normal or mildly elevated |
| MRI brachial plexus |
Exclude compression |
May show nerve enlargement |
| Nerve ultrasound |
Structural assessment |
Focal nerve enlargement |
MMN must be distinguished from:
| Condition |
Distinguishing Features |
| CIDP |
Sensory involvement, symmetric, responds to steroids |
| Motor neuron disease (ALS) |
Upper motor neuron signs, sensory spared but progressive |
| Progressive muscular atrophy |
Pure motor, more rapid progression |
| Multifocal acquired demyelinating sensory and motor (MADSAM) |
Sensory involvement |
| Vasculitic neuropathy |
Pain, systemic features, asymmetric |
| Nerve compression |
Single nerve territory, no conduction block elsewhere |
| Lead neuropathy |
Wrist drop, associated features |
- Detailed history: Onset, progression, family history
- Neurological examination: Focus on asymmetry and distribution
- Electrodiagnostic studies: Detailed motor and sensory NCS
- Anti-ganglioside antibodies: GM1, GD1a
- MRI: Exclude compressive lesions
- Blood work: Rule out mimics (diabetes, thyroid, B12)
IVIG is the treatment of choice with dramatic response in most patients 9:
| Parameter |
Recommendation |
| Dose |
2 g/kg (total) over 2-5 days |
| Maintenance |
1-2 g/kg every 2-4 weeks |
| Onset of effect |
Days to 2 weeks |
| Response rate |
70-80% |
| Long-term safety |
Generally good |
Mechanism of action:
- Blockade of Fc receptors
- Modulation of complement
- Neutralization of pathogenic antibodies
- Effects on B-cell function
An alternative for patients unable to receive IVIG 10:
- Similar efficacy to IVIG
- More frequent administration (weekly)
- Better tolerability for some patients
- Home-based administration possible
For IVIG-refractory cases 11:
| Parameter |
Recommendation |
| Dose |
500-750 mg/m² IV monthly |
| Duration |
6-12 months |
| Monitoring |
CBC, liver function |
| Side effects |
Myelosuppression, hemorrhagic cystitis |
Anti-CD20 monoclonal antibody 12:
- Emerging evidence for efficacy
- Particularly in anti-GM1 positive patients
- 375 mg/m² weekly × 4 weeks
- Repeat dosing based on response
| Treatment |
Evidence |
Note |
| Corticosteroids |
No benefit |
May worsen (unlike CIDP) |
| Plasma exchange |
Limited |
Not routinely used |
| Azathioprine |
Insufficient |
May be considered |
| Mycophenolate |
Insufficient |
Case reports only |
- Physical therapy: Maintains strength, prevents contractures
- Occupational therapy: Adaptive devices
- Orthotics: Ankle-foot orthoses for foot drop
- Gabapentin: First-line for neuropathic pain
- Pregabalin: Alternative
- Tricyclic antidepressants: Nortriptyline, amitriptyline
- Energy conservation: Pacing activities
- Exercise: Graded exercise program
- Sleep hygiene: Optimize rest
| Outcome |
Proportion |
Notes |
| Stable with treatment |
60-70% |
IVIG maintains function |
| Progressive despite treatment |
20-30% |
May need escalation |
| Spontaneous improvement |
5-10% |
Rare, usually temporary |
- Disability Rating Scale: Modified for MMN
- MRC sum score: Quantitative strength assessment
- Hand function tests: 9-hole peg test, grip strength
- Quality of life measures: SF-36, fatigue scales
- Generally good life expectancy: With appropriate treatment
- Respiratory involvement: Rare but serious complication
- Cause of death: Usually unrelated to MMN